latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/biopharma-eps-growth-expected-even-as-pandemic-hits-q1-20-sales-8211-analysts-57996751 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biopharma EPS growth expected even as pandemic hits Q1'20 sales – analysts

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biopharma EPS growth expected even as pandemic hits Q1'20 sales – analysts

Drugmakers will report earnings for the first quarter of 2020 in the midst of a worldwide pandemic that has markets reeling, and analysts expect revenue to be down almost across the board for the largest pharmaceutical and biotech companies.

Despite falling revenue, experts believe the biopharma industry will be relatively resilient to negative market forces than other areas of the healthcare industry due to strong fundamentals and a mostly intact supply chain.

Of the largest drugmakers by market capitalization, only Bristol-Myers Squibb Co. and Germany's Bayer AG are expected to see revenues rise from fourth-quarter 2019 levels, according to consensus operating estimates. However, many companies can expect revenues to be higher than in the first quarter of 2019.

EPS is also expected to rise for many of the top pharmaceutical companies despite the global market crisis, according to analysts.

The first of the big drugmakers to report earnings April 14 is Johnson & Johnson, which is also the largest by market capitalization. Cowen analyst Joshua Jennings said in an April 9 note that the company is likely to report a decline in sales in its medical devices business, although its pharmaceutical and consumer units should perform better.

Although Jennings tempered previous growth assumptions, he said J&J is better insulated from the impact of COVID-19 — the respiratory disease caused by the novel coronavirus — than its peers in the space. Still, the company is not immune, he said.

SNL Image